AXA (OTCMKTS:AXAHY) Raised to “Hold” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of AXA (OTCMKTS:AXAHY) from a sell rating to a hold rating in a research note issued to investors on Friday morning, Zacks.com reports.

According to Zacks, “The AXA Group is an international group of insurance and related financial services companies. AXA’s insurance operations are diverse geographically, with activities in 50 countries, principally Western Europe, North America and the Asia/Pacific area. In the United States, AXA is represented through its 60% holding in The Equitable companies and its subsidiaries, Equitable Life, Alliance Capital management and Donaldson, Lufkin & Jenrette. “

Separately, ValuEngine upgraded AXA from a sell rating to a hold rating in a research report on Friday, May 3rd. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of Buy.

AXA stock opened at $26.20 on Friday. The company has a quick ratio of 0.10, a current ratio of 0.10 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $64.02 billion, a price-to-earnings ratio of 8.59, a PEG ratio of 1.64 and a beta of 1.05. AXA has a 12 month low of $20.84 and a 12 month high of $27.93.

AXA Company Profile

AXA SA, through its subsidiaries, provides insurance and asset management services worldwide. It operates in seven segments: France, Europe, Asia, AXA XL, the United States, International, and Transversal & Central Holdings. The company offers a range of insurance products, including life and savings, property and casualty, and health.

See Also: CD Ladder

Get a free copy of the Zacks research report on AXA (AXAHY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AXA (OTCMKTS:AXAHY)

Receive News & Ratings for AXA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AXA and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

NuVasive  Upgraded at BidaskClub
NuVasive Upgraded at BidaskClub
Financial Contrast: Open Text  versus Asure Software
Financial Contrast: Open Text versus Asure Software
Zymeworks  & Checkpoint Therapeutics  Head-To-Head Survey
Zymeworks & Checkpoint Therapeutics Head-To-Head Survey
Head to Head Contrast: PermRock Royalty Trust  and Its Rivals
Head to Head Contrast: PermRock Royalty Trust and Its Rivals
Valvoline  Upgraded at Zacks Investment Research
Valvoline Upgraded at Zacks Investment Research
Crowdstrike  Price Target Raised to $104.00
Crowdstrike Price Target Raised to $104.00


 
© 2006-2019 Zolmax.